Loading data for EMCURE.BO — first visit, this takes a few seconds.
Emcure Pharmaceuticals Limited (EMCURE.BO)
BSE: EMCURE.BO
· Real-Time Price · USD
1,927.15
-1.40 (-0.07%)
At close: Sep 07, 2026, 9:58 AM
The price, the headline numbers and the latest news, in one place.
Emcure Pharmaceuticals Limited (EMCURE.BO) Stock Price, Analysis & Data
No data available
| Bid | 1925.4 |
| Market Cap | 366B |
| Revenue (ttm) | 96.8B |
| Net Income (ttm) | 10.1B |
| -0.07 | |
| 53.42 | |
| 36.08 | |
| 24.83 | |
| P/B (ttm) | 7.38 |
| P/S (ttm) | 3.77 |
| Earnings Date | n/a |
| Ask | 1931.3 |
| Volume | 10,479 |
| Avg. Volume (20D) | 27,158 |
| Open | 1932.05 |
| Previous Close | 1928.55 |
| Day's Range | 1915.00 - 1960.00 |
| 52-Week Range | 1260.10 - 2047.40 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $3.60 (0.19%) |
| Ex-Dividend Date | Sep 4, 2026 |
About EMCURE.BO
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure ...
Sector Healthcare
IPO Date Jul 10, 2024
Employees 6,914
Stock Exchange BSE
Ticker Symbol EMCURE.BO
Website https://www.emcure.com
Financial Performance
In 2026, Emcure Pharmaceuticals's revenue was 92.04B, an increase of 16.56% compared to the previous year's 78.96B. Earnings were 9.24B, an increase of 35.67%.
Financial numbers in INR Financial StatementsEarnings Surprise
Emcure Pharmaceuticals has released their quarterly earnings on Aug 6, 2026:
- Revenue of $25.8B misses estimates by $0, with 22.85% YoY growth.
- EPS of 15.34 exceeds estimates by 2.74, with 38.70% YoY growth.
